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The initial part of this presentation will focus on an 
overview of the literature and theory around the 
collection and use of patient reported outcomes (PROs) in 
oncological clinical practice. The second part will focus on 
the use of PROs to collect symptomatic radiotherapy 
toxicity data and develop normal tissue complication 
probability (NTCP) models using examples from RCTs and 
clinical practice. 
Improvements in cancer survival have led to an increasing 
number of patients with significant long-term adverse 
events/toxicity. The multiple modalities used to treat 
cancer make monitoring toxicity challenging and a 
systematic method of documenting acute and late adverse 
events has yet to be used in routine care. Increasingly 
PROs have been included in clinical trials as a standard 
data source for subjective patient experience. Research 
shows good concordance between patient and clinician 
evaluated toxicity with patients providing data on a wider 
range and milder toxicities. 
The integration of PRO results for use in routine practice 
has been found in multiple RCTs to improve patient-
clinician communication and symptom management 
without lengthening the duration of the consultation. 
Increasingly, electronic systems have been used to collect 
and integrate PRO results within existing electronic health 
records systems. Electronic methods are acceptable to 
patients and provide better quality data. They also 
provide the opportunity for remote monitoring of 
symptoms. However, there are a number of technical and 
procedural barriers that must be considered when 
implementing a complex intervention. International 
examples will be presented alongside experiences from 
our research group. 
The international committee QUANTEC (Quantitative 
Analysis of Normal Tissue Effects in the Clinic) aimed to 
establish best practice guidelines to help clinicians and 
treatment planners to determine acceptable dose/volume 
constraints to minimise toxicity to normal tissue. One of 
the key recommendations was the inclusion of PROs in 
toxicity assessment alongside clinician-reporting in 
routine clinical practice to define clinically relevant 
endpoints and aim to standardise outcome measures. 
Development of predictive models for normal tissue 
complications requires a detailed evaluation of the 
relationship between dosimetric, patient and clinical 
factors, as well as accurate measures of toxicity. 
Illustrative examples where PRO data has been 
incorporated within NTCP models from RCTs and 
observational study experience from our research group 
will be presented. 
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The utilization of Patient Reported Outcomes (PROs) in 
clinical trials have become widespread but data collection 
from such studies is not always consistent or fully reported 
leaving gaps in our knowledge of treatment consequences 
and quality of life. PROs focus on physical symptoms, 
treatment toxicities, psychosocial problems or global 
health related quality of life and the impacts of the 
disease and treatment from the patient’s perspective. 
PROs are therefore critical to understanding the 
consequences of radiotherapy from a ‘whole-person’ 
perspective and the impact of treatment on people’s lives 
[1]. To this end PROs have become an important tool for 
clinical trials to reflect not only the differences between 
therapies from the personal perspective but also 
predictors of health and treatment factors that may 
influence cancer outcomes. In view of their importance 
there is a need to ensure rigorous PRO data collection and 
analysis within clinical trials. 
Despite their importance PROs have not always been able 
to demonstrate significant long-term changes in QOL when 
evaluating new radiotherapy techniques. In reviewing 
radiotherapy clinical trials PRO generic quality of life tools 
tend to be more widely used [2]. These generic tools 
provide population based data that are useful for 
comparison in large studies but can be strongly influenced 
by environmental factors. Improving diversity of PROs by 
combining a range of instruments to demonstrate 
granularity can improve sensitivity of PROs to change. It is 
important to target measures and review the sensitivity of 
current measures to detect PRO changes as emerging 
radiotherapy treatments evolve.  Furthermore, PROs can 
be influenced by non-radiotherapy factors such as 
comorbidities, other cancer treatments, age, health 
status as well as health care provided. Over time there is 
a so called ‘response shift’ as patients become used to 
chronic symptoms and adapt their lives improving QOL 
scores despite symptom occurrence. These effects should 
be mitigated within randomization. 
Improving the rigor of how PROs are used in clinical trials 
is essential for good data capture and the credibility of 
future radiotherapy evidence. A survey of PRO research 
staff found that the timing of PRO measures within UK 
clinical trials varies substantially i.e. prior to the 
participant’s clinical consultation or after, by post or via 
help from a research nurse. These small differences can 
impact on participant’s responses and subsequent data 
quality [3]. Use of reminders and digital capture 
